These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 31490549)

  • 21. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
    Chan JY; LaPara K; Yee D
    Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
    Fan P; Agboke FA; Cunliffe HE; Ramos P; Jordan VC
    Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
    Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
    Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
    Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
    Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
    Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
    Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
    Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
    Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
    Drury SC; Detre S; Leary A; Salter J; Reis-Filho J; Barbashina V; Marchio C; Lopez-Knowles E; Ghazoui Z; Habben K; Arbogast S; Johnston S; Dowsett M
    Endocr Relat Cancer; 2011 Oct; 18(5):565-77. PubMed ID: 21734071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
    Wu J; Chen K; Zhang F; Jin J; Zhang N; Li D; Ying L; Chen W; Yu H; Mao W; Su D
    Cancer Med; 2017 Jun; 6(6):1353-1361. PubMed ID: 28440057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
    Bhargava R; Beriwal S; McManus K; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
    Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
    Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.